Merck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens: report

As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. | As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a treatment for COVID-19 under an emergency use authorization during the pandemic.

Raccontata dafiercepharma.com